Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations

European Journal of Clinical Pharmacology

Volumn 54, Issue 5, 1998, Pages 431-435

  Wanwimolruk, S ^a   Bhawan, S ^a   Coville, P F ^a   Chalcroft, S C W ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

CYP2C19; CYP2D6; Polynesian

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; PROGUANIL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; NEW ZEALAND; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; CHLOROGUANIDE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; POLYMORPHISM, GENETIC; POLYNESIA; REPRODUCIBILITY OF RESULTS;

EID: 0031875471     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050488     Document Type: Article

References (29)

1. Alván G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533-537
2. Basci NE, Brosen K, Bozkurt A, Isimer A, Sayal A, Kayaalp SO (1994) S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphism in a Turkish population. Br J Clin Pharmacol 38: 463-465
3. Bertilsson L, Lou Y-Q, Du Y-I, Liu Y, Kuang T-Y, Liao X-M, Wang K-Y, Reviriego J, Iselius L, Sjöqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylation of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51: 388-397
4. Bellwood PS (1987) The Polynesians. Thames and Hudson. London
5. Caporaso N, Pickle L (1989) Debrisoquine phenotype and genotype in Chinese. Lancet 2: 1534-1535
6. Edstein MD, Shanks GD, Teja-Isavadharm P, Rieckmann KH, Wehster HK (1994) Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. Br J Clin Pharmacol 37: 67-70
7. Eichelbaum M, Gross AS (1992) The genetic polymorphism of debrisoquine sparteine metabolism clinical aspects. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon Press, New York, pp 625-648
8. Haywood GA (1975) Human acetylation polymorphism in Polynesians. Proc Univ Otago Med Sch 53: 67-68
9. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM (1990) The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 30: 593-598
10. Horai Y, Nakono M, Ishizaki T, Ishikawa K, Zhou HH, Liao CL, Zhang LM (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46: 198-207
11. Kalow W (1982) Ethnic differences in drug metabolism. Clin Pharmacokinet 7: 373-400
12. Kayaalp SO, Basci NE, Bozkurt A, Kortunay S, Isimer A, Sayal A (1996) Polymorphic oxidation of proguanil in a Turkish population. Abstract in the VI World Conference on Clinical Pharmacology and Therapeutics. 4-9 August 1996. Buenos Aires, Argentina
13. Lee EJD, Nam YP, Hee GN (1988) Oxidation phenotyping in Chinese and Malay populations. Clin Exp Pharmacol Physiol 15: 889-891
14. Lennard MS (1990) Genetic polymorphism of sparteine debrisoquine oxidation: a reappraisal. Pharmacol Toxicol 67: 273-283
15. Lou YC, Ying L, Bertilsson L, Sjöqvist F (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 2: 852-853
16. Melton T, Peterson R, Redd AJ, Saha N, Sofro ASM, Martinson J, Stoneking M (1995) Polynesian genetic affinities with Southeast Asian populations as identified by mtDNA analysis. Am J Human Genet 57: 403-414
17. Nakamura K, Goto F, Ray WA, MeAllister CD, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402-408
18. Pearl GF, Boutagy J, Shenfield GM (1986) Debrisoquine oxidation in an Australian population. Br J Clin Pharmacol 21: 465-471
19. Price-Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a while British population. J Med Genet 17: 102-105
20. Price-Evans DA, Krahn P, Narayanan N (1995) The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 5: 64-71
21. Iss intergenic 9 base pair deletion in human mitochondrial DNAs from the Pacific. Mol Biol Evol 12: 604-615
22. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T (1994) Dapsone N-acetylation, metoprolol α-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial. Clin Pharmacol Ther 56: 142-153
23. Somogyi AA, Reinhard HA, Bochner F (1996) Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. Br J Clin Pharmacol 41: 175-179
24. Wanwimolruk S, Ferry DG (1990) Rapid high-performance liquid chromatographic method for the analysis of dehrisoquine and 4-hydroxydebrisoquine in urine without derivatization. J Liq Chromatogr 13: 961-968
25. Wanwimolruk S, Pratt EL (1995) A simple HPLC assay for proguanil and its active metabolite cycloguanil: application to oxidation polymorphism. J Liq Chromatogr 18: 4097-4105
26. Wamvimolruk S, Lee EJD, Patamasucon P (1990) Evidence for the polymorphic oxidation of dehrisoquine in the Thai population. Br J Clin Pharmacol 29: 244-247
27. Wanwimolruk S, Denton JR, Ferry DG, Beasley M, Broughton JR (1992) Polymorphism of dehrisoquine oxidation in New Zealand Caucasians. Eur J Clin Pharmacol 42: 349-350
28. Wanwimolruk S, Pratt HL, Denton JR, Chalcroft SCAV, Barron PA, Broughton JR (1995a) Evidence for the polymorphic oxidation of dehrisoquine and proguanil in a New Zealand Maori population. Pharmacogenetics 5: 193-198
29. Wanwimolruk S, Thou MR, Woods DJ (1995b) Evidence for the polymorphic oxidation and proguanil in a Khmer (Cambodian) population. Br J Clin Pharmacol 40: 166-169